1363281-27-9Relevant articles and documents
Discovery of VU0409551/JNJ-46778212: An mGlu5 Positive Allosteric Modulator Clinical Candidate Targeting Schizophrenia
Conde-Ceide, Susana,Martínez-Viturro, Carlos M.,Alcázar, Jesús,Garcia-Barrantes, Pedro M.,Lavreysen, Hilde,Mackie, Claire,Vinson, Paige N.,Rook, Jerri M.,Bridges, Thomas M.,Daniels, J. Scott,Megens, Anton,Langlois, Xavier,Drinkenburg, Wilhelmus H.,Ahnaou, Abdellah,Niswender, Colleen M.,Jones, Carrie K.,Macdonald, Gregor J.,Steckler, Thomas,Conn, P. Jeffrey,Stauffer, Shaun R.,Bartolomé-Nebreda, José Manuel,Lindsley, Craig W.
, p. 716 - 720 (2015/06/23)
Herein, we report the structure-activity relationship of a novel series of (2(phenoxymethyl)-6,7-dihydrooxazolo[5,4-c]pyridine-5(4H)-yl(aryl)methanones as potent, selective, and orally bioavailable metabotropic glutamate receptor subtype 5 (mGlu5/su